Atmo Biosciences Expands U.S. Operations for Gastrointestinal Diagnostic Tech

Atmo Biosciences, an Australian health innovator, is successfully bringing its groundbreaking diagnostic technology to the United States.

In 2025, the company received FDA clearance for its ingestible gas-sensing capsule, a device designed to revolutionize how clinicians diagnose gastrointestinal motility disorders like gastroparesis.

This pill-sized capsule travels through the digestive tract, wirelessly measuring gases to provide objective, non-invasive data on gut transit times.

Unlike traditional tests that involve radiation, this method allows patients to maintain their daily routine during the evaluation.

Following a successful commercial launch in the Northeast, the company has seen impressive 700% revenue growth by April 2026.

Based in San Diego, the company is now focused on broad distribution within hospitals and specialty clinics.

While currently focused on motility, Atmo is also investigating the capsule’s future potential in diagnosing conditions like IBS and SIBO.

With proven clinical validation and strong physician adoption, Atmo Biosciences is rapidly establishing itself as a key player in the U.S. medical device market.